$200,000.00 in Sales Expected for vTv Therapeutics Inc. (VTVT) This Quarter
Brokerages forecast that vTv Therapeutics Inc. (NASDAQ:VTVT) will announce $200,000.00 in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for vTv Therapeutics’ earnings. The highest sales estimate is $200,000.00 and the lowest is $190,000.00. vTv Therapeutics reported sales of $40,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 400%. The business is scheduled to issue its next earnings report on Wednesday, November 1st.
On average, analysts expect that vTv Therapeutics will report full-year sales of $200,000.00 for the current fiscal year, with estimates ranging from $200,000.00 to $30.43 million. For the next financial year, analysts expect that the company will report sales of $15.10 million per share, with estimates ranging from $200,000.00 to $30.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow vTv Therapeutics.
vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.02. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.19 million.
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research raised shares of vTv Therapeutics from a “sell” rating to a “buy” rating and set a $4.75 price objective on the stock in a research report on Tuesday, August 8th. HC Wainwright set a $13.00 price objective on shares of vTv Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. Finally, Canaccord Genuity reissued a “buy” rating and set a $15.00 price objective on shares of vTv Therapeutics in a research report on Friday, August 4th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $14.25.
In other vTv Therapeutics news, major shareholder Ronald O. Perelman bought 10,000 shares of the stock in a transaction that occurred on Wednesday, August 16th. The shares were bought at an average price of $4.97 per share, for a total transaction of $49,700.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Ronald O. Perelman bought 50,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was acquired at an average price of $4.72 per share, for a total transaction of $236,000.00. The disclosure for this purchase can be found here. Insiders have bought a total of 165,000 shares of company stock worth $728,150 in the last three months. Insiders own 0.80% of the company’s stock.
Several large investors have recently bought and sold shares of VTVT. State Street Corp raised its stake in vTv Therapeutics by 2.1% in the second quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock worth $486,000 after buying an additional 1,976 shares in the last quarter. Ameriprise Financial Inc. raised its stake in vTv Therapeutics by 62.7% in the second quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock worth $1,313,000 after buying an additional 101,850 shares in the last quarter. Renaissance Technologies LLC raised its stake in vTv Therapeutics by 4.8% in the first quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock worth $418,000 after buying an additional 2,900 shares in the last quarter. Sphera Funds Management LTD. raised its stake in vTv Therapeutics by 50.0% in the first quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biotechnology company’s stock worth $1,965,000 after buying an additional 100,000 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in vTv Therapeutics by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,305 shares in the last quarter. Institutional investors own 11.05% of the company’s stock.
vTv Therapeutics (VTVT) traded up 3.19% during midday trading on Friday, reaching $5.17. The company had a trading volume of 12,075 shares. vTv Therapeutics has a one year low of $3.57 and a one year high of $7.50. The company’s market capitalization is $50.11 million. The stock’s 50 day moving average is $4.54 and its 200 day moving average is $5.21.
ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/29/200000-00-in-sales-expected-for-vtv-therapeutics-inc-vtvt-this-quarter.html.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related stocks with our FREE daily email newsletter.